This patient has resistant hypertension, defined as uncontrolled blood pressure despite the use of three antihypertensive agents from different classes, including a diuretic. The presence of mild hypokalemia in this setting is highly suggestive of primary aldosteronism, the most common cause of secondary hypertension. Therefore, the most appropriate next step is to screen for this condition by measuring plasma aldosterone concentration and plasma renin activity. An aldosterone-to-renin ratio is then calculated to make the diagnosis.

This patient is presenting with a hypertensive emergency, characterized by severe hypertension and evidence of end-organ damage (hypertensive encephalopathy with confusion and papilledema). The initial goal of management is to carefully lower the blood pressure to prevent further organ damage without causing cerebral hypoperfusion. The standard recommendation is to lower the mean arterial pressure (MAP) by no more than 10-20% in the first hour, and then by another 5-15% over the next 23 hours. Rapidly lowering the blood pressure to normal or near-normal levels can precipitate ischemic injury.

This patient has symptomatic peripheral artery disease (PAD). PAD is considered a coronary artery disease risk equivalent, and patients are at very high risk for myocardial infarction, stroke, and cardiovascular death. The cornerstone of medical management is aggressive cardiovascular risk factor modification. All patients with PAD should be on high-intensity statin therapy (e.g., atorvastatin 40-80 mg or rosuvastatin 20-40 mg) regardless of their baseline LDL-cholesterol level to reduce this risk. Cilostazol is used for symptom relief of claudication but does not reduce cardiovascular events. Dual antiplatelet therapy is not routinely recommended for stable PAD. Intervention is reserved for lifestyle-limiting symptoms refractory to medical therapy or for critical limb ischemia.

The management of asymptomatic carotid stenosis is controversial, and the benefit of intervention (carotid endarterectomy [CEA] or stenting) is small and diminishes with advanced age, particularly in women. The primary management strategy is optimal medical therapy, which includes antiplatelet agents (aspirin), high-intensity statins, and aggressive blood pressure control. Given her age, sex, and asymptomatic status, the risks of a perioperative stroke from CEA likely outweigh the potential benefits of stroke reduction compared to continuing medical therapy alone. Dual antiplatelet therapy is not indicated for stable, asymptomatic stenosis.

The patient's presentation of severe, new-onset hypertension at a young age, particularly in a female, along with an abdominal bruit, is highly suspicious for secondary hypertension due to renal artery stenosis caused by fibromuscular dysplasia (FMD). FMD is a non-atherosclerotic, non-inflammatory vascular disease that most commonly affects the renal and internal carotid arteries. CT angiography or MR angiography of the renal arteries is the preferred non-invasive imaging modality to visualize the characteristic 'string of beads' appearance of FMD.

The patient is experiencing a classic ACE inhibitor-induced cough. This side effect is due to the accumulation of bradykinin and is not dose-dependent. Given his comorbidities of diabetes and chronic kidney disease, continued blockade of the renin-angiotensin-aldosterone system (RAAS) is indicated for its reno- and cardioprotective benefits. The most appropriate management is to switch from an ACE inhibitor (lisinopril) to an angiotensin II receptor blocker (ARB) like losartan. ARBs do not affect bradykinin levels and are therefore not associated with cough, while providing similar RAAS blockade benefits.

The patient's presentation, including upper extremity hypertension, diminished lower extremity pulses (brachial-femoral delay), and symptoms of leg claudication, is classic for coarctation of the aorta. In this condition, chronic aortic obstruction leads to the development of collateral circulation through the intercostal and internal mammary arteries to bypass the stenosis. The enlarged, pulsatile intercostal arteries cause pressure erosion on the inferior surfaces of the ribs, leading to the characteristic finding of rib notching on chest radiography.

The abstract shows that the composite primary endpoint was met (statistically significant reduction). However, when breaking down the composite endpoint, the benefit was driven entirely by a reduction in major adverse limb events (MALE), as the hazard ratio for major adverse cardiovascular events (MACE) was not statistically significant. Therefore, the most accurate conclusion is that Drug X reduces limb-related events but was not shown to reduce MACE (MI, stroke, cardiovascular death). Choice D is true, but A is more specific and accurately describes the components of the outcome. Choice B is an overstatement, and Choice C incorrectly dismisses the significant primary endpoint result.

This patient's presentation is classic for Takayasu arteritis, a large-vessel vasculitis that primarily affects the aorta and its major branches. It typically occurs in women younger than 50, often of Asian descent. The clinical picture includes systemic constitutional symptoms (fever, fatigue), evidence of vascular inflammation (elevated ESR), and signs of vessel stenosis such as blood pressure discrepancies between limbs, arterial bruits, and limb claudication. Giant cell arteritis affects patients >50. FMD does not cause systemic inflammation. Polyarteritis nodosa is a medium-vessel vasculitis that typically spares the aorta.

This question requires selecting an antihypertensive agent based on its effect on a comorbid condition. Among the angiotensin II receptor blockers (ARBs), losartan has a unique uricosuric effect, meaning it increases the urinary excretion of uric acid and can lower serum uric acid levels. This makes it a particularly good choice for patients with both hypertension and gout. In contrast, thiazide diuretics like hydrochlorothiazide are known to increase serum uric acid and can precipitate gout flares. While ACE inhibitors and beta-blockers are options for hypertension, they do not offer the specific benefit for hyperuricemia that losartan does.